Prognose

Das durchschnittliche Kursziel der Analysten beträgt +6,50€(+61,29%). Der Median liegt bei +4,43€(+9,93%).

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now
Karyopharm Therapeutics (KPTI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.» Mehr auf zacks.com
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 521.6% in Karyopharm Therapeutics (KPTI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.» Mehr auf zacks.com
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference
NEWTON, Mass. , May 19, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2025 RBC Capital Markets Global Healthcare Conference in a fireside chat on Wednesday, May 21 at 10:00 a.m.» Mehr auf prnewswire.com

Im letzten Quartal hatte Karyopharm Therapeutics einen Umsatz von 27,74 Mio€ und ein Nettoeinkommen von −21,69 Mio€